Background: Controversy exists regarding internal mammary lymph nodes (IMNs
) in the staging and treatment of breast cancer, Sentinel lymph node identi
fication with radiocolloid can map drainage to IMNs and directed biopsy can
be performed with minimal morbidity. Furthermore, recent studies suggest t
hat IMN drainage of breast tumors may be underestimated. To gain further in
sight into the prognostic value of IMNs, we reviewed the outcome of patient
s in whom the IMN status was routinely assessed.
Methods: A retrospective review of 286 patients with breast cancer who unde
rwent IMN dissection between 1956 and 1987 was conducted.
Results: Median follow-up is 186 months, age was 52 years (range, 21-85 yea
rs), tumor size was 2.5 cm, and number of IMNs removed was 5 (range, 1-22);
44% received chemotherapy, 16% endocrine therapy, and 5% radiotherapy. Pre
sence of IMN metastases correlated with primary tumor size (P < .0001) and
number of positive axillary nodes (P < .0001) but did not correlate with pr
imary tumor location or age. Overall, the 20-year disease-free survival is
significantly worse for the 25% of patients with IMN metastases (P < .0001)
. In patients with positive axillary nodes and tumors smaller than 2 cm, th
ere was a significantly worse survival (P < .0001) in the patients with IMN
metastases. This difference in survival was not seen in women with turners
larger than 2 cm,
Conclusions: Patients with IMN metastases. regardless of axillary node stat
us, have a highly significant decrease in 20-year disease-free survival. Tr
eatment strategies based on knowledge of sentinel IMN status may lead to im
provement in survival, especially for patients with small tumors. Ar presen
t, sentinel IMN biopsies should be performed in a clinical trial setting.